Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) treated with 2-chlorodeoxyadenosine

Pediatric Blood and Cancer

Volumn 47, Issue 5, 2006, Pages 612-615

  Tasso, M ^a   Esquembre, C ^a   Blanco, E ^a   Moscardo C ^a   Niveiro, M ^a   Paya A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

2 CdA; 2 chlorodeoxyadenosine; Cladribine; Rosai Dorfman disease; Sinus histiocytosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLADRIBINE; CLARITHROMYCIN; CORTICOSTEROID; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PURINE DERIVATIVE; STEROID; VINBLASTINE;

ARTICLE; BONE SCINTISCANNING; CANCER REGRESSION; CASE REPORT; CERVICAL LYMPHADENOPATHY; FEVER; HUMAN; HYPERGAMMAGLOBULINEMIA; LEUKOCYTOSIS; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; ROSAI DORFMAN DISEASE; SCHOOL CHILD; SINUS HISTIOCYTOSIS; TREATMENT OUTCOME;

CHILD; CLADRIBINE; FOLLOW-UP STUDIES; HISTIOCYTOSIS, SINUS; HUMANS; MALE; REMISSION INDUCTION; TREATMENT OUTCOME; X-RAYS;

EID: 33748514571     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20668     Document Type: Article

References (25)

1. Rosai J, Dorman RF. Sinus histiocytosis with massive lymphadenopathy: A newly recognized benign clinicopathological entity. Arch Pathol Lab Med 1969;87:63-70.
2. Lasak JM, Mikaelian DO, McCue P. Sinus histiocytosis: A rare cause of progressive pediatric cervical adenopathy. Otolaryngol Head Neck Surg 1999;120:765-769.
3. Horneff G, Heribert J, Hort W, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfamn Disease): Response to methotrexate and mercaptopurine. Med Pediatr Oncol 1996;27:187-192.
4. Malone M. The histiocytosis of childhood. Histiopathology 1991;19:105-119.
5. Rosai J. Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy). In: Rosai J, editor. Rosai and Ackerman surgical pathology, 9th edn. St. Louis: Mosby; 2004. pp 1911-1913.
6. Das DK, Gulati A, Bhatt NC, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Report of two cases with fine-needle aspiration cytology. Diagn Cytopathol 2001;24:42-45.
7. Desphande V, Verma K. Fine needle aspiration (FNA) cytology of Rosai-Dorfman disease. Cytopathology 1998;9:329-333.
8. Stastny JF, Wilkerson ML, Hamati HF, et al. Cytologic features of sinus histiocytosis with massive lymphadenopathy. A report of three cases. Acta Cytol 1997;41:871-876.
9. Foss HD, Herbst H, Araujo I, et al. Monokine expression in Langerhans cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Pathol 1996;179:60-65.
10. Willman CL, Busque L, Griffith BB, et al. Langerhans cell histiocytosis. A clonal proliferative disease. N Eng J Med 1994;331:154-160.
11. Marmaduke DP, Rosai J, Warnke R, et al. Molecular assessment of clonality in sinus histiocytosis with massive limphadenopathy (SHML). A reactive disorder of polyclonal histiocytes. Mod Pathol 1996;9:117A.
12. Foucar E, Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: An analysis of 14 deaths occurring in a patient registry. Cancer 1984;9:1834-1840.
13. Komp DM. The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Semin Diagn Pathol 1990;7:83-86.
14. Horzeff G, Jurgens H, Mort W, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Response to methotrexate and mercaptopurine. Med Ped Oncol 1996;27:187-192.
15. Gadner H, Chairperson. Histiocyte Society: Langerhans cell histiocytosis treatment protocol of the Second International Study. Vienna, Austria: Histiocyte Society Study Reference Center 1996. pp 2-21.
16. Antonius JI, Farid SM, Baez-Giangreco A. Steroid-responsive Rosai-Dorfman disease. Ped Hematol Oncol 1996;13:563-570.
17. Guchelaar H-J, Richel DJ, Schaafsma MR. Clinical and toxicological aspects of the anti-neoplastic drug cladribine: A review. Ann Hematol 1994;69:223-230.
18. Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocitic leukemia. J Clin Oncol 1995;13:570-574.
19. Jalyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. Cancer 1993;72:5-16.
20. Santana VM, Mirro J, Jr., Kearns C, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-370.
21. Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-Chlorodeoxyadenosine. Am J Hematol 2002;69:179-184.
22. Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogs in the therapy of Langerhans cell histiocytosis: A survey of the Histiocyte Society and review of the literature. Med Pediatr Oncol 1999;33:476-481.
23. Watts A, Files B. Langerhans cell histiocytosis: Central nervous system involvement treated successfully with 2-Chlorodeoxyadenosine. Pediatr Hematol Oncol 2001;18:199-204.
24. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-Chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001;19:2804-2811.
25. Vahdat L, Wong EG, Wile MJ, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994;84:3429-3434.